News
2h
Zacks Investment Research on MSNSepterna Stock Surges on Oral Obesity Drug Deal With Novo NordiskShares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
21h
GlobalData on MSNNovo Nordisk taps Septerna in $2.2bn deal for oral obesity therapiesNovo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.
Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results